Hospira Inc (HSP) 87.35 $HSP
Shares of HSP Up 68.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Feb 13, 9:09AM CST
SmarTrend identified an Uptrend for Hospira (NYSE:HSP) on October 24th, 2014 at $51.84. In approximately 4 months, Hospira has returned 68.56% as of today's recent price of $87.38.
HSP: 87.35 (unch)
Technical Notes Covering Pharma Equities -- Valeant Pharma Intl., Salix Pharma, Medicines, Hospira, and Horizon Pharma
PR Newswire - Fri Feb 13, 7:45AM CST
Editor Note: For more information about this release, please scroll to bottom.
VRX: 167.00 (-0.50), MDCO: 29.79 (+0.91), HZNP: 16.84 (-0.41), SLXP: 152.35 (+3.17), HSP: 87.35 (unch), VRX.TO: 207.95 (-1.47)
Biosimilar firms up on Remicade patent rejection
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 11:56AM CST
JNJ: 99.62 (+1.18), PFE: 34.64 (-0.23), AMGN: 153.48 (+0.30), EPRS: 7.67 (+0.67), PFNX: 12.45 (+0.29), HSP: 87.35 (unch), NVS: 102.20 (-0.17), CHRS: 27.11 (-0.71)
Lannett Near Buy Point After Earnings Beat
at Investor's Business Daily - Thu Feb 12, 10:50AM CST
With the market outlook improving and leading stocks showing healthier action, generic drugmaker Lannett (LCI) is closing in on a potential buy point. The Philadelphia-based firm, which is in the same Medical-Generic Drugs industry group as top-rated...
LCI: 57.78 (-0.91), AKRX: 47.28 (-0.25), HSP: 87.35 (unch)
Next Resistance Level for Hospira (HSP) is $87.54
Comtex SmarTrend(R) - Thu Feb 12, 10:44AM CST
Hospira (NYSE:HSP) has opened bullishly above the pivot of $87.39 today and has reached the first level of resistance at $87.44. Should the shares continue to rise, the resistance pivots of $87.54 and $87.69 will be of interest.
HSP: 87.35 (unch)
Hospira Beats on Q4 Earnings, Set to Be Acquired by Pfizer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 12, 9:28AM CST
Hospira's fourth-quarter 2014 adjusted earnings of 53 cents per share easily beat the Zacks Consensus Estimate of 41 cents.
ALNY: 95.54 (+1.67), ACHN: 10.89 (-0.20), PFE: 34.64 (-0.23), HSP: 87.35 (unch)
BioScrip's Turnaround Story Will Turn Around Some Heads
Douglas E. Johnston - at Seeking Alpha - Thu Feb 12, 7:56AM CST
BIOS: 6.04 (-0.06), HSP: 87.35 (unch)
Hospira (HSP) Q4 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Feb 12, 7:55AM CST
HSP: 87.35 (unch)
Hospira (HSP) Beats on Q4 Earnings, Revenues In Line - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 12, 7:42AM CST
Hospira (HSP) Beats on Q4 Earnings, Revenues In Line
HSP: 87.35 (unch)
Hospira Q4 operating income off 25%
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 7:38AM CST
HSP: 87.35 (unch)
Hospira beats by $0.12, revenue in-line
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 6:35AM CST
HSP: 87.35 (unch)
Hospira Reports Fourth-Quarter and Full-Year 2014 Results
PR Newswire - Thu Feb 12, 6:30AM CST
Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars, today reported results for the fourth quarter and full year ended Dec. 31, 2014. For the fourth quarter of 2014, net sales were $1.1 billion, and adjusted* diluted earnings per share were $0.53. (Adjusted* measures exclude certain specified items as described later in this press release and the attached schedules.) On a U.S. Generally Accepted Accounting Principles (GAAP) basis, fourth-quarter 2014 diluted earnings per share were $0.21. For full-year 2014, net sales were $4.5 billion, and adjusted* diluted earnings per share were $2.59. On a GAAP basis, full-year 2014 diluted earnings per share were $1.95.
HSP: 87.35 (unch)
Notable earnings before Thursday’s open
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 4:30PM CST
NLSN: 45.59 (+2.02), RTIX: 5.54 (+0.19), AAP: 150.16 (-1.26), JAH: 51.18 (+0.18), LMNS: 10.80 (+0.57), THS: 80.00 (-1.57), RWLK: 17.40 (-0.77), CAB: 53.55 (+1.23), FAF: 37.00 (+0.10), HSP: 87.35 (unch), PNK: 25.64 (-0.35), MFA: 7.89 (unch), SPW: 87.37 (-2.81), MFC: 17.31 (+0.27), HIMX: 8.04 (+0.28), LNCE: 30.72 (-0.25), TIME: 24.84 (+0.35), AVP: 9.08 (+0.39), INCY: 75.94 (+0.28), NNN: 41.00 (+0.20), NWE: 53.61 (-0.85), COR: 48.08 (+1.08), MHFI: 102.19 (unch), NCI: 14.99 (-0.01), BWA: 60.17 (-1.21), HERO: 0.92 (+0.02), NRP: 7.86 (-0.45), STC: 37.85 (+0.23), AB: 27.17 (+0.47), CPLA: 65.23 (-1.37), TU: 34.83 (+0.01), IFF: 116.96 (+2.19), GNC: 48.11 (-0.55), MINI: 40.62 (-0.83), ACOR: 36.14 (-0.51), CVE: 19.42 (-0.29), SNI: 73.00 (+0.39), CCE: 43.69 (-0.66), K: 63.20 (-0.10), DPS: 76.95 (-1.35), BG: 82.22 (+1.78), AAWW: 48.01 (+0.44), Q: 63.31 (+0.06), SHPG: 239.82 (+6.11), MANU: 17.20 (-0.21), MPEL: 27.54 (+0.78), APA: 67.05 (+2.47), DBD: 35.82 (+1.07), MPW: 14.64 (+0.14), HE: 33.14 (-0.22), RYN: 28.02 (-1.15), CS: 23.65 (+0.23), PDS: 6.04 (+0.12), ANR: 1.27 (+0.03), SON: 46.65 (-0.79), SKYW: 13.84 (+1.88), LPNT: 69.04 (-0.06), RDN: 16.10 (-0.43), MDWD: 7.22 (+0.17), SCOR: 53.35 (-1.10), FLO: 21.68 (+0.38)
Why Pfizer Might Not Split Anytime Soon
Emerging Equities - at Seeking Alpha - Wed Feb 11, 3:42PM CST
PFE: 34.64 (-0.23), AZN: 69.96 (+0.20), HSP: 87.35 (unch)
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Commences an Investigation of the Board of Directors of Hospira Inc. Regarding the Fairness of the Sale of the Company to Pfizer - HSP
Business Wire - Wed Feb 11, 11:49AM CST
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Hospira Inc. (NYSE: HSP) ("Hospira"
in connection with the sale of the Company to Pfizer.
HSP: 87.35 (unch)
Pfenex Up on Lucentis Biosimilar Collaboration with Hospira - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 11, 11:30AM CST
Hospira (HSP) inked a deal with Pfenex Inc. (PFNX) for the development and global commercialization of PF582, a biosimilar of Lucentis (eye treatment).
ABAX: 60.93 (+0.65), PFE: 34.64 (-0.23), PFNX: 12.45 (+0.29), HSP: 87.35 (unch)
HOSPIRA, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
Business Wire - Tue Feb 10, 3:59PM CST
Rigrodsky & Long, P.A.:
PFE: 34.64 (-0.23), HSP: 87.35 (unch)
Pfizer Starts Accelerated $5B Share Repurchase Program - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 1:43PM CST
Pfizer Inc. (PFE) announced that it has entered into an accelerated share repurchase agreement with Goldman, Sachs & Co. (GS) whereby it will repurchase $5 billion of its common stock.
AGN: 229.49 (+1.87), GS: 189.00 (-0.78), PFE: 34.64 (-0.23), HSP: 87.35 (unch)
SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Hospira, Inc. And Encourages Investors To Contact The Firm For Additional Information
Business Wire - Tue Feb 10, 12:40PM CST
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Hospira, Inc. ("Hospira" or the "Company" (NYSE: HSP) relating to the proposed buyout of the Company by Pfizer Inc. ("Pfizer" .
HSP: 87.35 (unch)
WeissLaw LLP: Hospira, Inc. Acquisition By Pfizer Inc. May Not Be In The Best Interest of HSP Shareholders
PR Newswire - Tue Feb 10, 10:00AM CST
The fairness of the proposed acquisition of Hospira, Inc. ("Hospira" or the "Company" by Pfizer Inc. ("Pfizer" is being investigated by WeissLaw LLP, a national class action, shareholder rights law firm. The investigation focuses on possible breaches of fiduciary duty and other violations of law by the Board of Directors of Hospira for agreeing to sell the Company to Pfizer. On February 5, 2015, the Company announced a definitive agreement for Pfizer to acquire Hospira in a transaction valued at approximately $17 billion. Under the terms of the agreement, Hospira shareholders will receive $90 in cash for each Hospira share they own.
PFE: 34.64 (-0.23), HSP: 87.35 (unch)
Shares of HSP Up 68.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Feb 13, 9:09AM CST
SmarTrend identified an Uptrend for Hospira (NYSE:HSP) on October 24th, 2014 at $51.84. In approximately 4 months, Hospira has returned 68.56% as of today's recent price of $87.38.
HSP: 87.35 (unch)
Technical Notes Covering Pharma Equities -- Valeant Pharma Intl., Salix Pharma, Medicines, Hospira, and Horizon Pharma
PR Newswire - Fri Feb 13, 7:45AM CST
Editor Note: For more information about this release, please scroll to bottom.
VRX: 167.00 (-0.50), MDCO: 29.79 (+0.91), HZNP: 16.84 (-0.41), SLXP: 152.35 (+3.17), HSP: 87.35 (unch), VRX.TO: 207.95 (-1.47)
Biosimilar firms up on Remicade patent rejection
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 11:56AM CST
JNJ: 99.62 (+1.18), PFE: 34.64 (-0.23), AMGN: 153.48 (+0.30), EPRS: 7.67 (+0.67), PFNX: 12.45 (+0.29), HSP: 87.35 (unch), NVS: 102.20 (-0.17), CHRS: 27.11 (-0.71)
Lannett Near Buy Point After Earnings Beat
at Investor's Business Daily - Thu Feb 12, 10:50AM CST
With the market outlook improving and leading stocks showing healthier action, generic drugmaker Lannett (LCI) is closing in on a potential buy point. The Philadelphia-based firm, which is in the same Medical-Generic Drugs industry group as top-rated...
LCI: 57.78 (-0.91), AKRX: 47.28 (-0.25), HSP: 87.35 (unch)
Next Resistance Level for Hospira (HSP) is $87.54
Comtex SmarTrend(R) - Thu Feb 12, 10:44AM CST
Hospira (NYSE:HSP) has opened bullishly above the pivot of $87.39 today and has reached the first level of resistance at $87.44. Should the shares continue to rise, the resistance pivots of $87.54 and $87.69 will be of interest.
HSP: 87.35 (unch)
Hospira Beats on Q4 Earnings, Set to Be Acquired by Pfizer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 12, 9:28AM CST
Hospira's fourth-quarter 2014 adjusted earnings of 53 cents per share easily beat the Zacks Consensus Estimate of 41 cents.
ALNY: 95.54 (+1.67), ACHN: 10.89 (-0.20), PFE: 34.64 (-0.23), HSP: 87.35 (unch)
BioScrip's Turnaround Story Will Turn Around Some Heads
Douglas E. Johnston - at Seeking Alpha - Thu Feb 12, 7:56AM CST
BIOS: 6.04 (-0.06), HSP: 87.35 (unch)
Hospira (HSP) Q4 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Feb 12, 7:55AM CST
HSP: 87.35 (unch)
Hospira (HSP) Beats on Q4 Earnings, Revenues In Line - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 12, 7:42AM CST
Hospira (HSP) Beats on Q4 Earnings, Revenues In Line
HSP: 87.35 (unch)
Hospira Q4 operating income off 25%
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 7:38AM CST
HSP: 87.35 (unch)
Hospira beats by $0.12, revenue in-line
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 6:35AM CST
HSP: 87.35 (unch)
Hospira Reports Fourth-Quarter and Full-Year 2014 Results
PR Newswire - Thu Feb 12, 6:30AM CST
Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars, today reported results for the fourth quarter and full year ended Dec. 31, 2014. For the fourth quarter of 2014, net sales were $1.1 billion, and adjusted* diluted earnings per share were $0.53. (Adjusted* measures exclude certain specified items as described later in this press release and the attached schedules.) On a U.S. Generally Accepted Accounting Principles (GAAP) basis, fourth-quarter 2014 diluted earnings per share were $0.21. For full-year 2014, net sales were $4.5 billion, and adjusted* diluted earnings per share were $2.59. On a GAAP basis, full-year 2014 diluted earnings per share were $1.95.
HSP: 87.35 (unch)
Notable earnings before Thursday’s open
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 4:30PM CST
NLSN: 45.59 (+2.02), RTIX: 5.54 (+0.19), AAP: 150.16 (-1.26), JAH: 51.18 (+0.18), LMNS: 10.80 (+0.57), THS: 80.00 (-1.57), RWLK: 17.40 (-0.77), CAB: 53.55 (+1.23), FAF: 37.00 (+0.10), HSP: 87.35 (unch), PNK: 25.64 (-0.35), MFA: 7.89 (unch), SPW: 87.37 (-2.81), MFC: 17.31 (+0.27), HIMX: 8.04 (+0.28), LNCE: 30.72 (-0.25), TIME: 24.84 (+0.35), AVP: 9.08 (+0.39), INCY: 75.94 (+0.28), NNN: 41.00 (+0.20), NWE: 53.61 (-0.85), COR: 48.08 (+1.08), MHFI: 102.19 (unch), NCI: 14.99 (-0.01), BWA: 60.17 (-1.21), HERO: 0.92 (+0.02), NRP: 7.86 (-0.45), STC: 37.85 (+0.23), AB: 27.17 (+0.47), CPLA: 65.23 (-1.37), TU: 34.83 (+0.01), IFF: 116.96 (+2.19), GNC: 48.11 (-0.55), MINI: 40.62 (-0.83), ACOR: 36.14 (-0.51), CVE: 19.42 (-0.29), SNI: 73.00 (+0.39), CCE: 43.69 (-0.66), K: 63.20 (-0.10), DPS: 76.95 (-1.35), BG: 82.22 (+1.78), AAWW: 48.01 (+0.44), Q: 63.31 (+0.06), SHPG: 239.82 (+6.11), MANU: 17.20 (-0.21), MPEL: 27.54 (+0.78), APA: 67.05 (+2.47), DBD: 35.82 (+1.07), MPW: 14.64 (+0.14), HE: 33.14 (-0.22), RYN: 28.02 (-1.15), CS: 23.65 (+0.23), PDS: 6.04 (+0.12), ANR: 1.27 (+0.03), SON: 46.65 (-0.79), SKYW: 13.84 (+1.88), LPNT: 69.04 (-0.06), RDN: 16.10 (-0.43), MDWD: 7.22 (+0.17), SCOR: 53.35 (-1.10), FLO: 21.68 (+0.38)
Why Pfizer Might Not Split Anytime Soon
Emerging Equities - at Seeking Alpha - Wed Feb 11, 3:42PM CST
PFE: 34.64 (-0.23), AZN: 69.96 (+0.20), HSP: 87.35 (unch)
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Commences an Investigation of the Board of Directors of Hospira Inc. Regarding the Fairness of the Sale of the Company to Pfizer - HSP
Business Wire - Wed Feb 11, 11:49AM CST
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Hospira Inc. (NYSE: HSP) ("Hospira"
in connection with the sale of the Company to Pfizer. HSP: 87.35 (unch)
Pfenex Up on Lucentis Biosimilar Collaboration with Hospira - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 11, 11:30AM CST
Hospira (HSP) inked a deal with Pfenex Inc. (PFNX) for the development and global commercialization of PF582, a biosimilar of Lucentis (eye treatment).
ABAX: 60.93 (+0.65), PFE: 34.64 (-0.23), PFNX: 12.45 (+0.29), HSP: 87.35 (unch)
HOSPIRA, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
Business Wire - Tue Feb 10, 3:59PM CST
Rigrodsky & Long, P.A.:
PFE: 34.64 (-0.23), HSP: 87.35 (unch)
Pfizer Starts Accelerated $5B Share Repurchase Program - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 1:43PM CST
Pfizer Inc. (PFE) announced that it has entered into an accelerated share repurchase agreement with Goldman, Sachs & Co. (GS) whereby it will repurchase $5 billion of its common stock.
AGN: 229.49 (+1.87), GS: 189.00 (-0.78), PFE: 34.64 (-0.23), HSP: 87.35 (unch)
SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Hospira, Inc. And Encourages Investors To Contact The Firm For Additional Information
Business Wire - Tue Feb 10, 12:40PM CST
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Hospira, Inc. ("Hospira" or the "Company"
(NYSE: HSP) relating to the proposed buyout of the Company by Pfizer Inc. ("Pfizer" . HSP: 87.35 (unch)
WeissLaw LLP: Hospira, Inc. Acquisition By Pfizer Inc. May Not Be In The Best Interest of HSP Shareholders
PR Newswire - Tue Feb 10, 10:00AM CST
The fairness of the proposed acquisition of Hospira, Inc. ("Hospira" or the "Company"
by Pfizer Inc. ("Pfizer" is being investigated by WeissLaw LLP, a national class action, shareholder rights law firm. The investigation focuses on possible breaches of fiduciary duty and other violations of law by the Board of Directors of Hospira for agreeing to sell the Company to Pfizer. On February 5, 2015, the Company announced a definitive agreement for Pfizer to acquire Hospira in a transaction valued at approximately $17 billion. Under the terms of the agreement, Hospira shareholders will receive $90 in cash for each Hospira share they own. PFE: 34.64 (-0.23), HSP: 87.35 (unch)
